Home NEWS AND MEDIA

Clinical | NeuExcell Therapeutics Reports Encouraging Clinical Results with In Situ Conversion Therapy for Malignant Glioma

05 Dec 2025

Related news

31 / May 2026

NeuExcell Therapeutics Announces Encouraging Data of NXL-004 in Recurrent Malignant Glioma at 2026 ASCO
Learn more
11 / Jun 2025

NeuExcell Therapeutics Announces First Dosing of NXL-001 in a Patient with Ten Years of Alzheimer's Disease
Learn more
08 / Mar 2025

NeuExcell Therapeutics Initiates First-in-Human Clinical Trial of NXL-001 to Treat Alzheimer's Disease
Learn more